Annual Report

The report presents Evotec's 2013 consolidated revenue of €85.9 million and year-end liquidity of €96.1 million. It describes expansion of Cure X and Target X partnerships, including collaborations with Harvard, Yale, and Dana-Farber, and a kidney-disease licence agreement with AstraZeneca. The Group ended the year with 610 employees after integrating CCS and closing its Indian operations.